Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6ZSZ6
UPID:
TSH1_HUMAN
Alternative names:
Antigen NY-CO-33; Serologically defined colon cancer antigen 33
Alternative UPACC:
Q6ZSZ6; O60534; Q4LE29; Q53EU4
Background:
Teashirt homolog 1, also known as Antigen NY-CO-33 and Serologically defined colon cancer antigen 33, is a probable transcriptional regulator implicated in developmental processes. It may function as a transcriptional repressor. This protein plays a crucial role in the development of the external auditory canal, with mutations affecting its gene linked to congenital aural atresia, a rare ear malformation.
Therapeutic significance:
Given its pivotal role in ear development and association with congenital aural atresia, targeting Teashirt homolog 1 could offer novel therapeutic avenues for treating this condition. Understanding the role of Teashirt homolog 1 could open doors to potential therapeutic strategies.